ClinicalTrials.gg
CompletedNCT00666575Updated Feb 2, 2021

A Study of the Safety of Gabapentin in a Potential Over-the-Counter Population With Occasional Sleeplessness

A Phase 3 interventional study of Gabapentin and Placebo in Transient Insomnia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 23 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-02-02.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,105
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders — none open to participants now, none under way, none of them phase 3. Gabapentin · Sleep Initiation and Maintenance Disorders.

Planned enrollment
Largest of 14
2,105 · median 283
Started
2004
with 4 others
Phase 3
9 of 14
none open now
Registered
3rd of 14
by date
Lead sponsor
9 of 14
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders, this one has the largest planned enrollment, is one of 5 that started in 2004, is one of 9 in phase 3, and was the 3rd registered.

Sleep Initiation and Maintenance Disorders

2,729 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

None of the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders is open now. The open studies under Sleep Initiation and Maintenance Disorders, anywhere →

Where they have run

About gabapentin

Gabapentin: first FDA approval 1993 (NEURONTIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing gabapentin in Sleep Initiation and Maintenance Disorders as a file.
02

Study summary

The purpose of this study is to assess the safety of gabapentin, as compared to placebo, in a potential over-the-counter population with reports of occasional sleeplessness

03

Conditions studied

  • Transient Insomnia
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects >/= 12 years of age who reported occasional sleeplessness in month prior to screening

Exclusion criteria

Exclusion Criteria:

  • Females who were pregnant or breastfeeding
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
2,105 participants (estimated)

Study arms

  • Experimental
    Gabapentin

    Drug: Gabapentin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days

  • DrugPlacebo

    Matched placebo oral capsule 30 minutes prior to bedtime for 28 days

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Time frame: Day 45

Secondary outcomes

  1. Pulse and Blood Pressure

    Time frame: Day 45

  2. Subjective proportion of nights having difficulty sleeping

    Time frame: Day 45

  3. Subjective Sleep Latency

    Time frame: Day 45

  4. Subjective Wake After Sleep Onset

    Time frame: Day 45

  5. Subjective Number of Awakenings

    Time frame: Day 45

  6. Subjective Total Sleep Time

    Time frame: Day 45

  7. Subjective Assessment of Sleep Quality

    Time frame: Day 45

  8. Subjective Assessment of Ease of Awakening

    Time frame: Day 45

  9. Subject Global Evaluation

    Time frame: Day 45

  10. Pittsburg Sleep Quality Index

    Time frame: Day 45

07

Study locations

23 sites
  • Pfizer Investigational Site
    Mobile, Alabama 36608, United States
  • Pfizer Investigational Site
    Phoenix, Arizona 85018, United States
  • Pfizer Investigational Site
    Beverly Hills, California 90211, United States
  • Pfizer Investigational Site
    San Francisco, California 94102, United States
  • Pfizer Investigational Site
    Clearwater, Florida 33765, United States
  • Pfizer Investigational Site
    DeLand, Florida 32720, United States
  • Pfizer Investigational Site
    New Port Richey, Florida 34652, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33024, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33409, United States
  • Pfizer Investigational Site
    Atlanta, Georgia 30328, United States
  • Pfizer Investigational Site
    Boise, Idaho 83704, United States
  • Pfizer Investigational Site
    Boise, Idaho 83712, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46250, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89104, United States
  • Pfizer Investigational Site
    Las Vegas, Nevada 89128, United States
  • Pfizer Investigational Site
    Santa Fe, New Mexico 87505, United States
  • Pfizer Investigational Site
    Nashville, Tennessee 37203, United States
  • Pfizer Investigational Site
    Austin, Texas 78705, United States
  • Pfizer Investigational Site
    Fort Worth, Texas 76135, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78205, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84102, United States
  • Pfizer Investigational Site
    West Jordan, Utah 84088, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2004 and a completion of May 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2008
First posted
Apr 25, 2008
Start
Dec 2004
CompletionActual
May 2005
Last update
Feb 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00666575
Responsible party
Sponsor
First posted
Apr 25, 2008
Start date
Dec 2004
Completion
May 2005
Last update
Feb 2, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion